MX2009006202A - Composiciones y metodos para el tratamiento de neoplasma. - Google Patents

Composiciones y metodos para el tratamiento de neoplasma.

Info

Publication number
MX2009006202A
MX2009006202A MX2009006202A MX2009006202A MX2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A
Authority
MX
Mexico
Prior art keywords
treating
compositions
methods
neoplasm
neoplasms
Prior art date
Application number
MX2009006202A
Other languages
English (en)
Spanish (es)
Inventor
Robert D Mass
Gregory D Plowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009006202A publication Critical patent/MX2009006202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009006202A 2006-12-11 2007-05-04 Composiciones y metodos para el tratamiento de neoplasma. MX2009006202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (1)

Publication Number Publication Date
MX2009006202A true MX2009006202A (es) 2009-06-22

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006202A MX2009006202A (es) 2006-12-11 2007-05-04 Composiciones y metodos para el tratamiento de neoplasma.

Country Status (17)

Country Link
US (1) US20100086544A1 (enExample)
EP (1) EP2099489B1 (enExample)
JP (1) JP2010512407A (enExample)
KR (1) KR101320198B1 (enExample)
CN (1) CN101547705B (enExample)
AU (1) AU2007333565A1 (enExample)
BR (1) BRPI0717688A2 (enExample)
CA (1) CA2670707A1 (enExample)
DK (1) DK2099489T3 (enExample)
IL (1) IL198852A (enExample)
MX (1) MX2009006202A (enExample)
NZ (1) NZ577058A (enExample)
RU (1) RU2482877C2 (enExample)
SG (1) SG177891A1 (enExample)
SI (1) SI2099489T1 (enExample)
WO (1) WO2008073509A2 (enExample)
ZA (1) ZA200903489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
CN107980040B (zh) 2015-07-27 2021-11-26 株式会社钟根堂 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物
HRP20201304T1 (hr) 2015-07-27 2020-11-27 Chong Kun Dang Pharmaceutical Corp. Spoj derivata 1,3,4-oksadiazol-amida koji služi kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji sadrži taj spoj
DK3331864T3 (da) 2015-08-04 2021-12-13 Chong Kun Dang Pharmaceutical Corp 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
MY196174A (en) 2015-10-12 2023-03-20 Chong Kun Dang Pharmaceutical Corp Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the Same
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN113874369B (zh) 2019-05-31 2024-08-27 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
DE59906030D1 (de) * 1998-09-25 2003-07-24 Boehringer Ingelheim Pharma Neue substituierte indolinone mit einer inhibierenden wirkung auf verschiedene kinasen und cyclin/cdk-komplexe
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Also Published As

Publication number Publication date
AU2007333565A1 (en) 2008-06-19
CN101547705A (zh) 2009-09-30
KR101320198B1 (ko) 2013-10-30
US20100086544A1 (en) 2010-04-08
WO2008073509A3 (en) 2009-01-08
ZA200903489B (en) 2010-08-25
RU2009126588A (ru) 2011-01-20
NZ577058A (en) 2012-04-27
CA2670707A1 (en) 2008-06-19
IL198852A0 (en) 2011-08-01
RU2482877C2 (ru) 2013-05-27
EP2099489A2 (en) 2009-09-16
HK1131064A1 (en) 2010-01-15
SG177891A1 (en) 2012-02-28
KR20090087908A (ko) 2009-08-18
SI2099489T1 (sl) 2014-09-30
IL198852A (en) 2013-06-27
DK2099489T3 (da) 2014-08-18
EP2099489B1 (en) 2014-05-21
JP2010512407A (ja) 2010-04-22
BRPI0717688A2 (pt) 2013-01-22
WO2008073509A2 (en) 2008-06-19
CN101547705B (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
MX2009006202A (es) Composiciones y metodos para el tratamiento de neoplasma.
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW200744568A (en) Epinephrine dosing regimens
MY172372A (en) Compositions and methods for lowering triglycerides
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
IL226717A0 (en) Antibodies@ofpeople@of@@@beta@and their use
MY151191A (en) Novel antibodies
IN2012DN00572A (enExample)
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EP2331093A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATMENT PREVENTING DISEASES
GB2466912A (en) Compositions and methods for treating lysosomal disorders
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
TW200727920A (en) New regimens for oral monophasic contraceptives
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
TW200700071A (en) Novel use
ZA200807281B (en) CCR5 antagonists useful for treating HIV
MX2013008559A (es) Derivados de leptina.
TN2010000463A1 (en) Compositions and methods for preparing and using same
MX2010003373A (es) Moduladores de receptores muscarinicos.
EP1722782A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING OR TREATING HIV-1

Legal Events

Date Code Title Description
FG Grant or registration